RT Journal Article
SR Electronic
T1 Lipid-lowering Drugs and Neurocognitive Function: A Systematic Review
JF In Vivo
JO In Vivo
FD International Institute of Anticancer Research
SP 3109
OP 3114
DO 10.21873/invivo.12144
VO 34
IS 6
A1 GEORGIOS KYRIAKOS
A1 LOURDES VICTORIA QUILES-SÁNCHEZ
A1 EVANGELOS DIAMANTIS
A1 PARASKEVI FARMAKI
A1 NIKOLAOS GARMPIS
A1 CHRISTOS DAMASKOS
A1 SPYRIDON SAVVANIS
A1 ALEXANDROS PATSOURAS
A1 ATHANASIA STELIANIDI
A1 ERRIKA VOUTYRITSA
A1 VASILIKI E. GEORGAKOPOULOU
A1 ANNA GARMPI
YR 2020
UL http://iv.iiarjournals.org/content/34/6/3109.abstract
AB Background/Aim: Lipid-lowering drugs have been suggested to affect neurocognitive function. This review aimed to give the latest evidence on the way these agents affect neurocognitive function based on clinical trials. Materials and Methods: A systematic search concerning original studies from 2015 to 2020 was performed through the databases PubMed, EMBASE and Cochrane, according to the PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses) guidelines. The trials enrolled numerous patients and were conducted in different areas of the world. The terms used are cholesterol, lipid-lowering drugs, statins and cognitive function. Results: Eleven randomized trials met the inclusion criteria. The trials included patients suffering from cardiovascular conditions. In particular, patients with coronary heart disease, coronary heart disease risk equivalents and hypercholesterolemia were tested. The trials included evolocumab, alirocumab, statin, ezetimibe or placebo. Conclusion: Lipid-lowering drugs seem to have no significant effect on neurocognitive function, but further research specifically focused on this matter is needed.